ERBB2 and neoplasm: Finally, when tumor samples were divided into four molecular subtypes, 71.4% of the triple-negative tumors (5/7), 58.3% of the HER2-positive (7/12) and 55.6% of the luminal B (10/18) showed at least one mutation.